copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Rigel Pharmaceuticals, Inc. (RIGL) Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer
Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib . . . "The resolution of this patent litigation underscores the strength of Rigel's intellectual property protecting TAVALISSE, an innovative treatment for people with immune thrombocytopenia," said Raul Rodriguez, Rigel's president and CEO
Pipeline :: Rigel Pharmaceuticals, Inc. (RIGL) Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases
Rigel Provides Business Update and 2025 Outlook Rigel continues to advance its Phase 1b clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of R289 in patients with relapsed or refractory (R R) lower-risk myelodysplastic syndrome (MDS)
Investor Relations :: Rigel Pharmaceuticals, Inc. (RIGL) Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS R289 1, Rigel's potent and selective dual inhibitor of IRAK1 and IRAK4, is being studied in an ongoing Phase 1b study evaluating the safety, tolerability, pharmacokinetics and preliminary activity in patients with LR-MDS who are relapsed or refractory to prior therapies
Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for . . . SOUTH SAN FRANCISCO, Calif , Oct 24, 2024 PRNewswire -- Rigel Pharmaceuticals, Inc ("Rigel") (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced it is issuing a Dear Health Care Provider (DHCP) letter related to a new safety signal for GAVRETO ® (pralsetinib) after
Rigel Pharmaceuticals Acquires U. S. Rights to GAVRETO® SOUTH SAN FRANCISCO, Calif , Feb 22, 2024 PRNewswire -- Rigel Pharmaceuticals, Inc ("Rigel") (Nasdaq: RIGL) today announced that it has entered into a definitive agreement to acquire the U S rights to GAVRETO ® (pralsetinib) from Blueprint Medicines Corporation ("Blueprint")